Physician
Hematology
Dr. J E. Sadler, MD
|
|
Give Review
Dr. J E. Sadler works in the field of Hematology. He studied medicine at Duke University School of Medicine. Duke University School of Medicine is a top medical university. Duke University School of Medicine is ranked 8 in research and 29 in primary care medicine He has 12 awards "Member", "Fellow", "Distinguished Career Award, Tenth Biennial Awards for Contributions to Hemostasis", "William Dameshek Prize", "Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology", "Investigator Recognition Award, Seventh / Eighth Biennial Awards for Contributions to Hemostasis", "Elected Member", "Sigma Xi", "Alpha Omega Alpha", "Everett S. Wallis Prize in Organic Chemistry", "Robert Thornton McCay Prize (Physical Chemistry)" and "Phi Beta Kappa". Doctor J E. Sadler, MD has written publications. He has 70 publications published with PubMed. The lastest publication is: 'Apical sorting of bovine enteropeptidase does not involve detergent-resistant association with sphingolipid-cholesterol rafts.' Doctor J E. Sadler, MD is registered with Medicare and accepts Medicare payments.
Publications
- Linker regions and flexibility around the metalloprotease domain account for conformational activation of ADAMTS-13.
- Thrombin-Targeted Liposomes Establish a Sustained Localized Anticlotting Barrier against Acute Thrombosis.
- An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.
- Phylogenetic and functional analysis of histidine residues essential for pH-dependent multimerization of von Willebrand factor.
- Functional architecture of Weibel-Palade bodies.
- Shiga toxin B subunits induce VWF secretion by human endothelial cells and thrombotic microangiopathy in ADAMTS13-deficient mice.
- Redeeming ristocetin.
- Unfolding the A2 domain of von Willebrand factor with the optical trap.
- A structural explanation for the antithrombotic activity of ARC1172, a DNA aptamer that binds von Willebrand factor domain A1.
- Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines.
- Integrin alpha(v)beta(3) on human endothelial cells binds von Willebrand factor strings under fluid shear stress.
- Low von Willebrand factor: sometimes a risk factor and sometimes a disease.
- Enteropeptidase, a type II transmembrane serine protease.
- Extensive contacts between ADAMTS13 exosites and von Willebrand factor domain A2 contribute to substrate specificity.
- Von Willebrand factor, ADAMTS13, and thrombotic thrombocytopenic purpura.
- Identification of amino acid residues responsible for von Willebrand factor binding to sulfatide by charged-to-alanine-scanning mutagenesis.
- Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress.
- Assembly of Weibel-Palade body-like tubules from N-terminal domains of von Willebrand factor.
- Pathogenesis of thrombotic microangiopathies.
- Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi.
- Exosite interactions contribute to tension-induced cleavage of von Willebrand factor by the antithrombotic ADAMTS13 metalloprotease.
- Identification of amino acid residues essential for heparin binding by the A1 domain of human von Willebrand factor.
- Zinc and calcium ions cooperatively modulate ADAMTS13 activity.
- Thrombotic thrombocytopenic purpura: a moving target.
- Cleavage of ultralarge multimers of von Willebrand factor by C-terminal-truncated mutants of ADAMTS-13 under flow.
- Binding of ADAMTS13 to von Willebrand factor.
- New concepts in von Willebrand disease.
- A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization.
- Proteomics, genomics and the future of medical education.
- Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.
- A recombinant murine meizothrombin precursor, prothrombin R157A/R268A, inhibits thrombosis in a model of acute carotid artery injury.
- Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic t...
- Recent advances in thrombotic thrombocytopenic purpura.
- Cleavage of the ADAMTS13 propeptide is not required for protease activity.
- Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin: insight into glycoprotein Ibalpha binding mechanism induced by snake venom...
- Cleavage of von Willebrand factor requires the spacer domain of the metalloprotease ADAMTS13.
- Aortic stenosis, von Willebrand factor, and bleeding.
- Structural biology. A ménage à trois in two configurations.
- Von Willebrand disease type 1: a diagnosis in search of a disease.
- Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab.
- A new name in thrombosis, ADAMTS13.
- ADAMTS13 and TTP.
- Biomedicine. Contact--how platelets touch von Willebrand factor.
- Identification of the regulatory elements of the human von Willebrand factor for binding to platelet GPIb. Importance of structural integrity of the regions flanked by...
- Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells.
- Characterization of the residues involved in the human alpha-thrombin-haemadin complex: an exosite II-binding inhibitor.
- Platelets: thrombotic thrombocytopenic purpura.
- Mutations in the proenteropeptidase gene are the molecular cause of congenital enteropeptidase deficiency.
- Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations o...
- Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.
- Report on the workshop: Von Willebrand factor and Thrombotic Thrombocytopenic Purpura.
- Platelet glycoprotein Ib alpha binds to thrombin anion-binding exosite II inducing allosteric changes in the activity of thrombin.
- Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.
- Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.
- Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion.
- Mechanism by which heparin proteoglycan modulates mast cell chymase activity.
- Apical sorting of bovine enteropeptidase does not involve detergent-resistant association with sphingolipid-cholesterol rafts.
- Incomplete embryonic lethality and fatal neonatal hemorrhage caused by prothrombin deficiency in mice.
- Activation of thrombin-activable fibrinolysis inhibitor requires epidermal growth factor-like domain 3 of thrombomodulin and is inhibited competitively by protein C.
- Structure of murine enterokinase (enteropeptidase) and expression in small intestine during development.
- Generation and characterization of mice deficient in hepsin, a hepatic transmembrane serine protease.
- Biochemistry and genetics of von Willebrand factor.
- Bovine proenteropeptidase is activated by trypsin, and the specificity of enteropeptidase depends on the heavy chain.
- Combined factors V and VIII deficiency climbs onto the map.
- Dominant type 1 von Willebrand disease caused by mutated cysteine residues in the D3 domain of von Willebrand factor.
- Structure and localization of the thrombin receptor gene on mouse chromosome 13.
- Analysis of Arg834Gln and Val902Glu type 2A von Willebrand disease mutations: studies with recombinant von Willebrand factor and correlation with patient characteristics.
- Identification of amino acid residues essential for von Willebrand factor binding to platelet glycoprotein Ib. Charged-to-alanine scanning mutagenesis of the A1 domain...
- cDNA sequence and chromosomal localization of human enterokinase, the proteolytic activator of trypsinogen.
Schools
Duke University
Duke University Med Center
University Wa Med Center
Doctors Specialties
- Internal Medicine
- Hematology
Accepted Insurances
Awards
- Member
- Fellow
- Distinguished Career Award, Tenth Biennial Awards for Contributions to Hemostasis
- William Dameshek Prize
- Fellow, Council on Arteriosclerosis, Thrombosis, and Vascular Biology
- Investigator Recognition Award, Seventh / Eighth Biennial Awards for Contributions to Hemostasis
- Elected Member
- Sigma Xi
- Alpha Omega Alpha
- Everett S. Wallis Prize in Organic Chemistry
- Robert Thornton McCay Prize (Physical Chemistry)
- Phi Beta Kappa
Education
-
University of Washington -
Duke University Hospital -
Duke University School of Medicine -
DUKE UNIVERSITY MEDICAL CENTER
Hospital
-
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1285651711 | |
| NPPES Provider LastName | SADLER | |
| NPPES Provider FirstName | J | |
| NPPES Provider ZIPCode | 631101032 | |
| NPPES Provider State | MO | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 17.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285651711 |
| Last Name Of The Provider | SADLER |
| First Name Of The Provider | J |
| View All |
Similar Doctors
|
|
Dr. John T. Ellena, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Albert M. Ding, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian R. Pierce, MD |
|
|
Tahir Qayum, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark Walshauser, MD |
|
|
Dr. Scott Wasserstrom, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sagun D. Goyal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jason J. Li, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karthik V. Iyer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brenda J. Grossman, MD |
|
|
Dr. Jesse W. Keller, MD |
|
|
Dr. James M. Epstein, MD |
|
|
Dr. Eric J. Duncavage, MD
This Doctor is OpenDoctor Recommended.
|